PBLS

Parabilis Medicines, Inc.

Parabilis Medicines, Inc. (PBLS) has 8 SEC Form 4 filings (29 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 22, 2026.

The most active filer is Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. with 4 filings. Insiders have net bought $441.4M over the trailing 6 months. The largest single insider purchase in this window was $423.8M by Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. on Jun 11, 2026.

  • Industry:Biotechnology
  • CEO:Mathai Mammen
  • Employees:145
  • HQ:Cambridge, MA, US
  • IPO:2026-06-10

Insider Buying

$441.4M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Unique Insiders

3

in the rolling window

Source
Purchase$3.6MJul 22SEC ↗
Purchase$1.9MJul 22SEC ↗
Purchase$1.4MJul 22SEC ↗
Levy GuyFirst filing
Purchase$10.0MJun 29SEC ↗
Purchase$233KJun 16SEC ↗
Purchase$240KJun 16SEC ↗
Purchase$423.8MJun 15SEC ↗
SEBULSKY ALANFirst filing
Purchase$250KJun 15SEC ↗

Related companies

Parabilis Medicines, Inc. is in the Healthcare sector.